E34.01
Carcinoid heart syndrome
Clinical Classification Guidelines
Inclusion Terms
- Carcinoid heart disease
- Hedinger syndrome
Medical Intelligence & Overview
Carcinoid heart syndrome, also known as Hedinger syndrome, is a rare condition that occurs in individuals with certain types of neuroendocrine tumors called carcinoid tumors. These tumors can produce specific chemicals that cause damage to the heart, leading to characteristic heart valve problems and other cardiovascular issues. Recognizing this syndrome is essential for timely management and preventing severe heart complications.
Causes & Symptoms
Clinical Causes: Presence of carcinoid tumors, primarily in the gastrointestinal tract or lungs Excess production of vasoactive substances such as serotonin, tachykinins, and other hormones by the tumor Metastatic spread of carcinoid tumors to the liver or other organs, allowing hormones to bypass liver metabolism and reach the heart Genetic factors influencing tumor growth and hormone secretion
Key Symptoms: Flushing episodes, often triggering skin redness and warmth Diarrhea or abdominal cramping due to hormone secretion Swelling in the legs and ankles, resulting from heart failure Shortness of breath or difficulty breathing, especially during physical activity Heart murmurs detected during medical examinations Fatigue and weakness Unexplained weight loss or loss of appetite
Diagnostic & Treatment
Diagnosis Path: Diagnosing carcinoid heart syndrome involves a combination of clinical assessment and specialized testing. Key diagnostic steps include: - **Blood Tests:** Measuring levels of hormones like serotonin and its metabolite, 5-HIAA, to confirm hormone overproduction - **Imaging Procedures:** Utilizing echocardiography to identify characteristic heart valve abnormalities, such as thickening and retraction of the valves, particularly on the right side of the heart - **Scintigraphy (OctreoScan):** Detecting carcinoid tumors and their metastases - **Cardiac MRI:** For detailed visualization of heart structures if needed - **Biopsy and Histological Examination:** To confirm tumor type and activity if applicable
Treatment Protocols: Managing carcinoid heart syndrome aims to control hormone secretion, reduce tumor load, and address heart valve damage. Treatment options include: - **Medical Therapy:** - Use of somatostatin analogs (e.g., octreotide, lanreotide) to inhibit hormone secretion - Symptomatic treatments such as diuretics for heart failure, and antihypertensives as needed - **Surgical Interventions:** - Valve surgery to repair or replace damaged valves, particularly on the right side of the heart - Resection of primary tumors or metastases in certain cases - **Supportive Care:** Regular monitoring of heart function and hormone levels, managing symptoms, and preventing complications - **Experimental and Adjunct Therapies:** Inclusion of targeted therapies or clinical trials, depending on individual cases and advancements in medical research
Clinical Advice & FAQs
Billing Guidance
Is E34.01 a billable ICD-10 code?
Yes, E34.01 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report E34.01?
Clinical documentation must specify the nature of Carcinoid heart syndrome and any associated comorbidities for accurate reporting.
Cite this Clinical Reference
